Multiplicity of mesenchymal stromal cells

finding the right route to therapy

Alison Wilson, Margeaux Hodgson-Garms, Jess Frith, Paul G Genever

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Over the last decade, the acceleration in the clinical use of mesenchymal stromal cells (MSCs) has been nothing short of spectacular. Perhaps most surprising is how little we know about the “MSC product.” Although MSCs are being delivered to patients at an alarming rate, the regulatory requirements for MSC therapies (for example in terms of quality assurance and quality control) are nowhere near the expectations of traditional pharmaceuticals. That said, the standards that define a chemical compound or purified recombinant protein cannot be applied with the same stringency to a cell-based therapy. Biological processes are dynamic, adaptive and variable. Heterogeneity will always exist or emerge within even the most rigorously sorted clonal cell populations. With MSCs, perhaps more so than any other therapeutic cell, heterogeneity pervades at multiple levels, from the sample source to the single cell. The research and clinical communities collectively need to recognize and take steps to address this troublesome truth, to ensure that the promise of MSC-based therapies is fulfilled.
Original languageEnglish
Article number1112
Number of pages8
JournalFrontiers in Immunology
Volume10
DOIs
Publication statusPublished - 16 May 2019

Cite this

Wilson, Alison ; Hodgson-Garms, Margeaux ; Frith, Jess ; Genever, Paul G. / Multiplicity of mesenchymal stromal cells : finding the right route to therapy. In: Frontiers in Immunology. 2019 ; Vol. 10.
@article{08281f4b54aa4458aca0b21c03a725d8,
title = "Multiplicity of mesenchymal stromal cells: finding the right route to therapy",
abstract = "Over the last decade, the acceleration in the clinical use of mesenchymal stromal cells (MSCs) has been nothing short of spectacular. Perhaps most surprising is how little we know about the “MSC product.” Although MSCs are being delivered to patients at an alarming rate, the regulatory requirements for MSC therapies (for example in terms of quality assurance and quality control) are nowhere near the expectations of traditional pharmaceuticals. That said, the standards that define a chemical compound or purified recombinant protein cannot be applied with the same stringency to a cell-based therapy. Biological processes are dynamic, adaptive and variable. Heterogeneity will always exist or emerge within even the most rigorously sorted clonal cell populations. With MSCs, perhaps more so than any other therapeutic cell, heterogeneity pervades at multiple levels, from the sample source to the single cell. The research and clinical communities collectively need to recognize and take steps to address this troublesome truth, to ensure that the promise of MSC-based therapies is fulfilled.",
author = "Alison Wilson and Margeaux Hodgson-Garms and Jess Frith and Genever, {Paul G}",
year = "2019",
month = "5",
day = "16",
doi = "10.3389/fimmu.2019.01112",
language = "English",
volume = "10",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media",

}

Multiplicity of mesenchymal stromal cells : finding the right route to therapy. / Wilson, Alison; Hodgson-Garms, Margeaux; Frith, Jess; Genever, Paul G.

In: Frontiers in Immunology, Vol. 10, 1112, 16.05.2019.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Multiplicity of mesenchymal stromal cells

T2 - finding the right route to therapy

AU - Wilson, Alison

AU - Hodgson-Garms, Margeaux

AU - Frith, Jess

AU - Genever, Paul G

PY - 2019/5/16

Y1 - 2019/5/16

N2 - Over the last decade, the acceleration in the clinical use of mesenchymal stromal cells (MSCs) has been nothing short of spectacular. Perhaps most surprising is how little we know about the “MSC product.” Although MSCs are being delivered to patients at an alarming rate, the regulatory requirements for MSC therapies (for example in terms of quality assurance and quality control) are nowhere near the expectations of traditional pharmaceuticals. That said, the standards that define a chemical compound or purified recombinant protein cannot be applied with the same stringency to a cell-based therapy. Biological processes are dynamic, adaptive and variable. Heterogeneity will always exist or emerge within even the most rigorously sorted clonal cell populations. With MSCs, perhaps more so than any other therapeutic cell, heterogeneity pervades at multiple levels, from the sample source to the single cell. The research and clinical communities collectively need to recognize and take steps to address this troublesome truth, to ensure that the promise of MSC-based therapies is fulfilled.

AB - Over the last decade, the acceleration in the clinical use of mesenchymal stromal cells (MSCs) has been nothing short of spectacular. Perhaps most surprising is how little we know about the “MSC product.” Although MSCs are being delivered to patients at an alarming rate, the regulatory requirements for MSC therapies (for example in terms of quality assurance and quality control) are nowhere near the expectations of traditional pharmaceuticals. That said, the standards that define a chemical compound or purified recombinant protein cannot be applied with the same stringency to a cell-based therapy. Biological processes are dynamic, adaptive and variable. Heterogeneity will always exist or emerge within even the most rigorously sorted clonal cell populations. With MSCs, perhaps more so than any other therapeutic cell, heterogeneity pervades at multiple levels, from the sample source to the single cell. The research and clinical communities collectively need to recognize and take steps to address this troublesome truth, to ensure that the promise of MSC-based therapies is fulfilled.

U2 - 10.3389/fimmu.2019.01112

DO - 10.3389/fimmu.2019.01112

M3 - Review Article

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 1112

ER -